Materias dentro de su búsqueda.
Mostrando 981 - 1,000 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.38s Limitar resultados
  1. 981
    “…Multiple subclones of HER2-amplified DCIS with distinct CNV profiles are observed, suggesting that multiple events occurred for the acquisition of HER2 amplification. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Transcriptome and genome evolution during HER2-amplified breast neoplasia
  2. 982
    “…This review will focus on the role of receptor tyrosine kinases of the human epidermal growth factor receptor (EGFR) family that is comprised EGFR itself, HER2, HER3 and HER4 in RMS onset and the potential therapeutic targeting of receptor tyrosine kinases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
  3. 983
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
  4. 984
    “…These molecules have been considered as a targeted strategy in the treatment of human cancers. HER2 tumor biomarker is a transmembrane tyrosine kinase receptor that can be used for targeted therapies in the forms of anti-HER2 monoclonal antibodies, antibody–drug conjugates and immunotoxins. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Recombinant immunotoxins development for HER2-based targeted cancer therapies
  5. 985
    “…Only 41.1% (65/158) of patients had histology and CTC HER2 status consistent with the remaining 58.9% (93/158) of patients, although their histological HER2 was positive, and CTC HER2 was negative. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
  6. 986
    Publicado 1854
    Enlace del recurso
    Online Artículo Texto
    Woman: Her Diseases and Remedies: A Series of Letters to His Class
  7. 987
    “…Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 complex, which drives cell-cycle progression and development of therapeutic resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
  8. 988
    “…SIMPLE SUMMARY: A proportion of breast tumors bear the oncogenic transmembrane tyrosine kinase protein HER2. Even though therapies that target HER2 have changed the prognosis and quality of life of patients with HER2+ breast tumors, resistance to those therapies is still an important clinical problem. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
  9. 989
    “…In 15%-30% of breast cancers, overexpression of the human epidermal growth factor receptor 2 (Her-2/neu) is associated with more aggressive tumor development. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccination against Her-2/neu, with focus on peptide-based vaccines
  10. 990
    por Wang, Fu-Wen, Ao, Xiang, Fu, Shao-Mei
    Publicado 2019
    “…A recent report showed that SOX11, an embryogenic mammary transcription factor, is overexpressed in breast cancer. HER2 is also dysregulated in breast cancer stem cells; however, the relative expression of these two genes in recurrent breast cancer has not been investigated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of SOX11 and HER2 and their association with recurrent breast cancer
  11. 991
    “…A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
  12. 992
    “…However, molecular targeted therapy is mainly aimed at HER2-positive breast cancer and has not yet achieved satisfactory curative effect on HER2-negative breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    New Advances in Targeted Therapy of HER2-Negative Breast Cancer
  13. 993
    “…HER2-positive inflammatory breast cancer (IBC) is associated with poor overall survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-Positive Inflammatory Breast Cancer Challenges of Clinical Practices
  14. 994
    “…In this review, we discuss the current therapeutic landscape for HER2-positive gastroesphageal cancer and the seminal clinical trials that have shaped our approach to this disease entity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
  15. 995
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Young woman with black spots and a red rash on her forearm
  16. 996
    “…This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
  17. 997
    “…About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
  18. 998
    “…Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by the epidermal growth factor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
  19. 999
    por Garg, Rachana, Jandial, Kai, Chen, Mike
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    GM-CSF - an oncogenic driver of HER2+ breast leptomeningeal metastasis
  20. 1000
    “…Both of these effects may result in enhanced HER activity.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improving the HER Activity and Stability of Pt Nanoparticles by Titanium Oxynitride Support
Herramientas de búsqueda: RSS